Robin Edwards

Robin Edwards has a diverse work experience in the field of translational medicine and oncology research. They have held senior leadership positions in various pharmaceutical companies, including Dragonfly Therapeutics, Inc. where they currently work as the SVP of Translational Medicine. Prior to this, they were the Vice President and Global Head of Translational Sciences & Biomarkers at Daiichi Sankyo, Inc. from December 2021 to May 2023.

Before joining Daiichi Sankyo, Inc., Robin worked at Bristol-Myers Squibb, where they held multiple roles, including Executive Director & Head of Translational Pathology, Group Director of Pathology, and Director of Integrative Scientist, Molecular Oncology. They worked at Bristol-Myers Squibb from October 2013 to December 2021.

Robin also has experience working at Merck as the Director of Clinical Research in Oncology from October 2010 to May 2013. Prior to Merck, they worked at Pfizer in various capacities, including Director of Translational Medicine, Biotherapeutics R&D, Associate Director, and Associate Director of Clinical Translational Medicine.

Their early career includes roles at the University of Pennsylvania School of Medicine as an Instructor and at Fox Chase Cancer Center as an Associate Member. Overall, Robin Edwards has a strong background in translational medicine and oncology research, with significant experience in leadership positions at major pharmaceutical companies.

Robin Edwards attended Case Western Reserve University School of Medicine from 1985 to 1989, where they obtained a medical degree (M.D.). Following this, from 1990 to 1997, Robin attended the University of Pennsylvania School of Medicine, specializing in pathology and hematopathology.